Healthcare costs sit in the political spotlight again after Democrats won Congress on an affordability platform, and that puts pressure on insurers, drugmakers and hospital chains to justify every dollar. Investors looking for potential long term beneficiaries often focus on businesses with solid finances and clear execution records. This article breaks down three leading healthcare stocks from a curated screener that filters for those qualities.
The three stocks discussed next are only a sample from this idea. The full screen surfaced 34 more healthcare companies across providers, equipment, tech, pharmaceuticals, biotech and life sciences, with similarly detailed stories that are not covered here. To see the broader opportunity set, analyze and identify your own high conviction healthcare picks directly in the Best Healthcare Stocks screener.
Eton Pharmaceuticals (ETON)
Eton Pharmaceuticals anchors this Best Healthcare Stocks screen through its focus on commercial treatments for rare conditions, especially in pediatric care. This gives you exposure to a focused specialty pharma player rather than a broad, diversified healthcare conglomerate.
Eton Pharmaceuticals develops and commercializes rare-disease therapies such as Increlex, Alkindi, Khindivi, Galzin and PKU Golike. It generates about US$106 million from prescription drug products, all in the United States, and the stock carries a market value of roughly US$1.46b.
"Accelerated diagnosis rates of rare diseases like Wilson disease and severe primary IGF-1 deficiency, driven by advances in genetic testing and physician education, are likely to expand Eton's addressable patient populations and contribute to sustained revenue growth over the next several years."
What ultimately matters is how one unresolved pressure shapes the balance between that potential growth and the profitability investors are counting on.
That balance between promise and profitability is exactly what the full narrative for Eton Pharmaceuticals unpacks, including how current pricing, pipeline risk and execution could reshape the story ahead.
BeOne Medicines (ONC)
BeOne Medicines leans into the Best Healthcare Stocks theme through a tightly focused oncology business built around marketed cancer drugs and a sizeable late stage pipeline. Together these give it real scale rather than a single experimental bet.
BeOne Medicines generates about US$6.1b from pharmaceutical products anchored by its oncology therapies and has a market value near US$40.4b, putting it in the upper tier of global cancer focused healthcare stocks by both revenue and market capitalization.
"The step up in free cash flow to US$161 million in the first quarter of 2026 and US$435 million in the second quarter of 2026, even while operating expenses grow in the mid teens and U.S. pricing commitments under the GENEROUS model limit list price upside, gives BeOne Medicines more internally generated capital to fund late stage programs and global launches without similar growth in share count, which is supportive for future earnings per share."
What could surprise investors now is how one pressure on this oncology engine ends up shaping the balance between future growth and profitability.
How that pressure plays out is exactly what the full narrative for BeOne Medicines unpacks, including where oncology cash flows could be accelerating faster than headline earnings suggest.
ADMA Biologics (ADMA)
ADMA Biologics fits the Best Healthcare Stocks theme through its commercial plasma derived IVIG therapies that target immune deficiency, backed by its own collection centers and biomanufacturing footprint. Together, these give this specialist a solid, therapy focused healthcare profile.
ADMA Biologics generates about US$494.7 million from its ADMA Biomanufacturing segment and US$17.4 million from Plasma Collection Centers, with a further US$0.1 million from licenses, and the stock carries a market value near US$2.5b.
ADMA Biologics matters here because its IVIG therapies are already in market, its manufacturing engine is scaled, and its balance between specialized care and industrial plasma operations fits the screener’s focus on real businesses serving clear medical needs.
"Rapidly increasing adoption and utilization of ASCENIV is being reinforced by real world data in 127 medically complex primary immunodeficiency patients and a May 2026 FDA label expansion into children aged 2 years and older."
What investors will watch now is how one quiet shift in the product mix eventually filters through to margins, cash generation and future reinvestment capacity.
As that mix shifts, the full narrative for ADMA Biologics shows how ASCENIV adoption, margins and funding capacity could be decoupling from what headline figures alone suggest.
Seeking Fresh Alternatives Before They Fly
Fresh ideas often move first. Slow money can end up chasing momentum after prices are already elevated. Scan these under the radar lists ahead of the crowd, while it matters, and consider your options early.
- Find under followed quality before momentum traders react by running the 19 high quality undiscovered gems while these businesses are still showing clues in quieter price action.
- Monitor cash rich balance sheets using the curated list of solid balance sheet and fundamentals (24 results) so you can review candidates before resilience is fully reflected in the price.
- Follow long-term demand trends in power and electrification by screening the 41 power grid technology and infrastructure stocks and filtering for businesses building the hardware that keeps grids operating.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com